|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008. GLOBOCAN. 2008. Int J Cancer. 127:2893–2917. 2008. View Article : Google Scholar
|
|
3
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geo-graphic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahn MS, Kang SY, Lee HW, Jeong SH, Park
JS, Lee KJ, et al: 5-fluorouracil, mitomycin-C, and
polysaccharide-K versus uracil-ftorafur and polysaccharide-K as
adjuvant chemoimmunotherapy for patients with locally advanced
gastric cancer with curative resection. Onkologie. 36:421–426.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yanagihara K, Ito A, Toge T and Numoto M:
Antiproliferative efects ofisoflavones on human cancer cell lines
established from the gastrointestinal tract. Cancer Res.
53:5815–5821. 1993.PubMed/NCBI
|
|
6
|
Tian F, Xu LH, Zhao W, Tian LJ and Ji XL:
The optimal therapeutic timing and mechanism of puerarin treatment
of spinal cord ischemia-reperfusion injury in rats. J
Ethnopharmacol. 134:892–896. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan Y, Zong J, Zhou H, Bian ZY, Deng W,
Dai J, et al: Puerarin attenuates pressure overload-induced cardiac
hypertrophy. J Cardiol. 63:73–81. 2014. View Article : Google Scholar
|
|
8
|
Zhao LX, Liu AC, Yu SW, Wang ZX, Lin XQ,
Zhai GX and Zhang QZ: The permeability of puerarin loaded poly
(butylcyanoacrylate) nanoparticles coated with polysorbate 80 on
the blood-brain barrier and its protective effect against cerebral
ischemia/reperfusion injury. Biol Pharm Bull. 36:1263–1270. 2013.
View Article : Google Scholar
|
|
9
|
Kim KM, Jung DH, Jang DS, Kim YS, Kim JM,
Kim HN, Surh YJ and Kim JS: Puerarin suppresses AGEs-induced
inflammation in mouse mesangial cells: a possible pathway through
the induction of heme oxygenase-1 expression. Toxicol Appl
Pharmacol. 244:106–113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu Z and Li W: Induction of apoptosis by
puerarin in colon cancer HT-29 cells. Cancer Lett. 238:53–60. 2006.
View Article : Google Scholar
|
|
11
|
Wang Y, Ma Y, Zheng Y, Song J, Yang X, Bi
C, Zhang D and Zhang Q: In vitro and in vivo anticancer activity of
a novel puerarin nanosuspension against colon cancer, with high
efficacy and low toxicity. Int J Pharm. 441:728–735. 2013.
View Article : Google Scholar
|
|
12
|
Chou TC and Talalay P: Quantitative
analysis of dose effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar
|
|
13
|
Chou TC, Motzer RJ, Tong Y and Bosl GJ:
Computerized quantitation of synergism and antagonism of taxol,
topotecan and cisplatin against human teratocarcinoma cell growth:
a rational approach to clinical protocol design. J Natl Cancer
Inst. 86:1517–1524. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ashraf N, Hoffe S and Kim R: Adjuvant
treatment for gastric cancer: chemotherapy versus radiation.
Oncologist. 18:1013–1021. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Imazawa M, Kojima T, Boku N, Onozawa Y,
Hironaka S, et al: Efficacy of sequential methotrexate and
5-fluorouracil (MTX/5FU) in improving oral intake in patients with
advanced gastric cancer with severe peritoneal dissemination.
Gastric Cancer. 12:153–157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim SL, Kim SH, Trang KT, Kim IH, Lee SO,
et al: Synergistic antitumor effect of 5-fluorouracil in
combination with parthenolide in human colorectal cancer. Cancer
Lett. 335:479–486. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J, Liu W, Zhao Q, Qi Q, Lu N, et al:
Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823
human gastric carcinoma. Toxicology. 256:135–140. 2009. View Article : Google Scholar
|
|
18
|
Nishino T, Yamamoto Y, Ikeda M, Morimoto
M, Furukawa T, Goto M, Furukita Y, Takechi H, Seike J, Tangoku A
and Fujiwara H: Pathological complete response in a case of
advanced esopha-geal cancer invading aorta treated by preoperative
chemotherapy with docetaxel and cisplatin plus 5-FU. Gan To Kagaku
Ryoho. 40:643–646. 2013.(In Japanese). PubMed/NCBI
|
|
19
|
Wang L, Wei PK and Xu YP: Experimental
study on puerarin injection reverse multidrug resistance of nude
mice of human gastric carcinoma constructed using orthotopic
transplantation. J Chendu Uni TCM. 28:42–46. 2005.(In Chinese).
|
|
20
|
Hien TT, Kim HG, Han EH, Kang KW and Jeong
HG: Molecular mechanism of suppression of MDR1 by puerarin from
pueraria lobata via NF-kappaB pathway and cAMP-responsive element
transcriptional activity-dependent up-regulation of AMP-activated
protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res.
54:918–928. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han P, Pei LY, Li J, Zhang L, Zhang HQ and
Xu D: Effect and mechanism of pueraria crude extract puerarin on
lung cancer H446 cell proliferation. Shandong Med J. 48:7–9.
2008.
|
